Business & Consumer Services » Computer Services | Xinjiang Baihuacun Co. Ltd.

Xinjiang Baihuacun Co. Ltd. A | Cash Flow

Fiscal year is January-December. All values CNY Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
5,822.70
353,457.00
543,743.50
56,175.70
565,094.40
812,979.60
Depreciation, Depletion & Amortization
203,945.80
172,190.10
171,346.30
109,599.30
19,677.20
28,352.80
Other Funds
57,466.60
279,302.80
501,175.20
607,331.30
2,812.20
925,393.60
Funds from Operations
360,553.70
6,964.50
57,166.50
26,069.00
78,135.30
140,628.10
Changes in Working Capital
353,918.20
195,324.20
484,435.80
130,851.90
128,374.40
59,131.20
Net Operating Cash Flow
6,635.50
202,288.70
427,269.20
104,782.90
50,239.10
81,496.90
Capital Expenditures
172,816.80
87,305.30
80,699.50
37,847.50
54,662.50
Sale of Fixed Assets & Businesses
1,385.60
1,000.60
808.00
20,247.50
130.00
Purchase/Sale of Investments
-
3,940.00
-
2,300.00
47,000.00
Net Investing Cash Flow
189,837.80
85,090.60
79,891.50
413,400.60
101,532.60
Issuance/Reduction of Debt, Net
125,400.00
384,550.00
752,000.00
21,235.30
61,563.10
Net Financing Cash Flow
67,933.40
105,247.20
250,824.80
628,566.60
64,375.30
Net Change in Cash
115,268.90
11,950.90
96,552.90
110,338.70
216,147.00
Free Cash Flow
166,181.30
114,983.40
346,569.80
142,630.40
104,901.60
Deferred Taxes & Investment Tax Credit
2,198.80
5,322.20
35,297.10
36,881.00
1,125.10
138.70
Net Assets from Acquisitions
18,406.60
-
-
353,005.60
-
Other Sources
-
5,154.10
-
-
-
Exchange Rate Effect
-
-
-
44.40
-
Other Uses
-
-
-
-
0.10

About Xinjiang Baihuacun Co.

View Profile
Address
141 Zhongshan Road
Urumqi Xinjiang Uygur 830002
China
Employees -
Website http://www.xjbhc.net
Updated 07/08/2019
Xinjiang Baihuacun Co., Ltd. provides medical research and development services as a contract research organization (CRO). Its services include pharmaceutical research and development, clinical trials, chemical synthesis related to drug research and development, screening and identification of compounds, preparation research and safety evaluation, pharmacology and toxicology experiments, new drug clinical approval and generic drug production approval, and related technical consultancy. The company was founded on April 20, 1959 and is headquartered in Urumqi, China.